This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Tue Jun 16, 9:09AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Celldex (CLDX), Teva Pharmaceutical (TEVA) and Eli Lilly & Co (LLY) with bullish sentiments.

Claim 55% Off TipRanks

Celldex (CLDX)

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Celldex, with a price target of $67.00. The company’s shares closed last Monday at $31.65.

According to TipRanks.com, Kluska is a 5-star analyst with an average return of 22.6% and a 47.6% success rate. Kluska covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Mereo Biopharma Group Plc, and Ultragenyx Pharmaceutical. ;'>

Celldex has an analyst consensus of Strong Buy, with a price target consensus of $49.33, which is a 57.7% upside from current levels. In a report issued on June 10, UBS also maintained a Buy rating on the stock with a $45.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Teva Pharmaceutical (TEVA)

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Teva Pharmaceutical, with a price target of $40.00. The company’s shares closed last Monday at $34.09.

According to TipRanks.com, Chen is a 4-star analyst with an average return of 3.3% and a 48.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Bristol-Myers Squibb, and Johnson & Johnson. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teva Pharmaceutical with a $42.38 average price target, a 21.4% upside from current levels. In a report released today, J.P. Morgan also maintained a Buy rating on the stock.

Eli Lilly & Co (LLY)

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Eli Lilly & Co, with a price target of $1300.00. The company’s shares closed last Monday at $1119.71.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 6.7% and a 51.4% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and ACADIA Pharmaceuticals. ;'>

Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $1266.21, implying an 11.7% upside from current levels. In a report issued on June 1, Barclays also maintained a Buy rating on the stock with a $1400.00 price target.

Read More on CLDX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).